Clinical outcomes of dogs with high-grade cutaneous mast cell tumors
ObjectivesTo evaluate the prognostic factors and treatment outcomes in dogs with high-grade cutaneous mast cell tumors (HGMCTs).MethodsMedical records of dogs with a histopathologic diagnosis of HGMCTs were reviewed from a single institution. Clinical factors, treatment-related variables, and adjuva...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Veterinary Science |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fvets.2024.1519636/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592402992332800 |
|---|---|
| author | Siew Mei Ong Siew Mei Ong Charly McKenna Christopher Pinard Christopher Pinard Christopher Pinard Christopher Pinard Danielle Richardson Michelle L. Oblak |
| author_facet | Siew Mei Ong Siew Mei Ong Charly McKenna Christopher Pinard Christopher Pinard Christopher Pinard Christopher Pinard Danielle Richardson Michelle L. Oblak |
| author_sort | Siew Mei Ong |
| collection | DOAJ |
| description | ObjectivesTo evaluate the prognostic factors and treatment outcomes in dogs with high-grade cutaneous mast cell tumors (HGMCTs).MethodsMedical records of dogs with a histopathologic diagnosis of HGMCTs were reviewed from a single institution. Clinical factors, treatment-related variables, and adjuvant therapies were documented to evaluate their association with clinical outcomes. Comparative and survival analyses were conducted using Kaplan–Meier survival analysis, log-rank, and Fisher’s exact tests.ResultsThe overall median survival time for the 77 dogs was 317 days (range 20–3,041 days) with 6-month, 1-year, and 2-year survival rates of 69, 50, and 30%, respectively. Surgically treated dogs had significantly prolonged survival and were 6.88 times more likely to survive beyond 5.5 months. The presence of metastasis at initial staging was strongly associated with poorer outcomes, as dogs without metastasis at initial staging had 6.94 times higher odds of surviving beyond 2 years. Surgical sites with incomplete margins had a higher local recurrence rate (58%) compared to those with clean margins (26%). Despite aggressive treatment, 75% of the dogs that received concurrent surgical and adjuvant therapy experienced disease progression. Lymph node extirpation, tumor localization, number of tumors, and local recurrence were not associated with the overall outcome.Clinical relevanceThe combination of aggressive local therapy and adjuvant systemic chemotherapy provides a notable survival benefit in dogs with HGMCTs. The limited therapeutic benefit of locoregional lymph node extirpation, combined with a persistently high metastatic rate despite systemic chemotherapy, highlights the critical need for more effective regional and systemic treatment approaches for HGMCT patients. |
| format | Article |
| id | doaj-art-2e0b8f91170f41c68485ed1aa2646fea |
| institution | Kabale University |
| issn | 2297-1769 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Veterinary Science |
| spelling | doaj-art-2e0b8f91170f41c68485ed1aa2646fea2025-01-21T08:36:49ZengFrontiers Media S.A.Frontiers in Veterinary Science2297-17692025-01-011110.3389/fvets.2024.15196361519636Clinical outcomes of dogs with high-grade cutaneous mast cell tumorsSiew Mei Ong0Siew Mei Ong1Charly McKenna2Christopher Pinard3Christopher Pinard4Christopher Pinard5Christopher Pinard6Danielle Richardson7Michelle L. Oblak8Department of Companion Animal Medicine and Surgery, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang, MalaysiaUPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang, MalaysiaDepartment of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, CanadaDepartment of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, CanadaDepartment of Oncology, Lakeshore Animal Health Partners, Mississauga, ON, CanadaCentre for Advancing Responsible & Ethical Artificial Intelligence, University of Guelph, Guelph, ON, CanadaANI.ML Research, ANI.ML Health Inc., Toronto, ON, CanadaDepartment of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, CanadaDepartment of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, CanadaObjectivesTo evaluate the prognostic factors and treatment outcomes in dogs with high-grade cutaneous mast cell tumors (HGMCTs).MethodsMedical records of dogs with a histopathologic diagnosis of HGMCTs were reviewed from a single institution. Clinical factors, treatment-related variables, and adjuvant therapies were documented to evaluate their association with clinical outcomes. Comparative and survival analyses were conducted using Kaplan–Meier survival analysis, log-rank, and Fisher’s exact tests.ResultsThe overall median survival time for the 77 dogs was 317 days (range 20–3,041 days) with 6-month, 1-year, and 2-year survival rates of 69, 50, and 30%, respectively. Surgically treated dogs had significantly prolonged survival and were 6.88 times more likely to survive beyond 5.5 months. The presence of metastasis at initial staging was strongly associated with poorer outcomes, as dogs without metastasis at initial staging had 6.94 times higher odds of surviving beyond 2 years. Surgical sites with incomplete margins had a higher local recurrence rate (58%) compared to those with clean margins (26%). Despite aggressive treatment, 75% of the dogs that received concurrent surgical and adjuvant therapy experienced disease progression. Lymph node extirpation, tumor localization, number of tumors, and local recurrence were not associated with the overall outcome.Clinical relevanceThe combination of aggressive local therapy and adjuvant systemic chemotherapy provides a notable survival benefit in dogs with HGMCTs. The limited therapeutic benefit of locoregional lymph node extirpation, combined with a persistently high metastatic rate despite systemic chemotherapy, highlights the critical need for more effective regional and systemic treatment approaches for HGMCT patients.https://www.frontiersin.org/articles/10.3389/fvets.2024.1519636/fullcaninehigh-grade cutaneous mast cell tumorsurgical excisionlymphadenectomyadjuvant therapy |
| spellingShingle | Siew Mei Ong Siew Mei Ong Charly McKenna Christopher Pinard Christopher Pinard Christopher Pinard Christopher Pinard Danielle Richardson Michelle L. Oblak Clinical outcomes of dogs with high-grade cutaneous mast cell tumors Frontiers in Veterinary Science canine high-grade cutaneous mast cell tumor surgical excision lymphadenectomy adjuvant therapy |
| title | Clinical outcomes of dogs with high-grade cutaneous mast cell tumors |
| title_full | Clinical outcomes of dogs with high-grade cutaneous mast cell tumors |
| title_fullStr | Clinical outcomes of dogs with high-grade cutaneous mast cell tumors |
| title_full_unstemmed | Clinical outcomes of dogs with high-grade cutaneous mast cell tumors |
| title_short | Clinical outcomes of dogs with high-grade cutaneous mast cell tumors |
| title_sort | clinical outcomes of dogs with high grade cutaneous mast cell tumors |
| topic | canine high-grade cutaneous mast cell tumor surgical excision lymphadenectomy adjuvant therapy |
| url | https://www.frontiersin.org/articles/10.3389/fvets.2024.1519636/full |
| work_keys_str_mv | AT siewmeiong clinicaloutcomesofdogswithhighgradecutaneousmastcelltumors AT siewmeiong clinicaloutcomesofdogswithhighgradecutaneousmastcelltumors AT charlymckenna clinicaloutcomesofdogswithhighgradecutaneousmastcelltumors AT christopherpinard clinicaloutcomesofdogswithhighgradecutaneousmastcelltumors AT christopherpinard clinicaloutcomesofdogswithhighgradecutaneousmastcelltumors AT christopherpinard clinicaloutcomesofdogswithhighgradecutaneousmastcelltumors AT christopherpinard clinicaloutcomesofdogswithhighgradecutaneousmastcelltumors AT daniellerichardson clinicaloutcomesofdogswithhighgradecutaneousmastcelltumors AT michelleloblak clinicaloutcomesofdogswithhighgradecutaneousmastcelltumors |